NCT03440437: FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy

NCT03440437
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Uncontrolled CNS metastases, primary CNS tumors, or solid tumors with CNS metastases as only measurable disease
https://ClinicalTrials.gov/show/NCT03440437

Comments are closed.

Up ↑